Egetis Therapeutics Ownership

Stocks Sweden . 
Stock . Egetis Therapeutics AB
EGTX Stock  SEK 5.60  0.04  0.71%   
Egetis Therapeutics holds a total of 249.59 Million outstanding shares. Egetis Therapeutics AB retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Egetis Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Egetis Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Egetis Therapeutics AB. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Egetis Stock Ownership Analysis

About 52.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.52. Some equities with similar Price to Book (P/B) outperform the market in the long run. Egetis Therapeutics recorded a loss per share of 0.7. The entity had not issued any dividends in recent years. Egetis Therapeutics AB , a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rareniche diseases with unmet medical needs in the orphan drug segment. Egetis Therapeutics AB was founded in 2006 and is based in Stockholm, Sweden. Egetis Therapeutics operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 11 people. To learn more about Egetis Therapeutics AB call the company at 46 86 79 72 10 or check out https://www.egetis.com.

Egetis Therapeutics Outstanding Bonds

Egetis Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Egetis Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Egetis bonds can be classified according to their maturity, which is the date when Egetis Therapeutics AB has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp Bond
US235822AB96		View
Volcan Compania Minera Corp Bond
USP98047AC08		View
Boeing Co 2196 Corp Bond
US097023DG73		View
HSBC Holdings PLC Corp Bond
US404280DR76		View
MPLX LP 4875 Corp Bond
US55336VAG59		View
MPLX LP 4125 Corp Bond
US55336VAK61		View
MPLX LP 52 Corp Bond
US55336VAL45		View
International Game Technology Corp Bond
US460599AD57		View

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Egetis Stock Analysis

When running Egetis Therapeutics' price analysis, check to measure Egetis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Egetis Therapeutics is operating at the current time. Most of Egetis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Egetis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Egetis Therapeutics' price. Additionally, you may evaluate how the addition of Egetis Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY